NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blo
September 15 2008 - 6:30AM
PR Newswire (US)
PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext
Paris: COX) today announced successful top-line results from the
second phase 3 study for naproxcinod in 1020 patients with
osteoarthritis of the knee (the 302 study). Both doses of
naproxcinod (750 mg and 375 mg bid) met the three co-primary
efficacy endpoints at week-13 (p